| Autor: |
King CS; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Ignacio RV; Department of Biostatistics and., Khangoora V; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Nyquist A; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Singhal A; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Thomas C; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Cantres OF; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Aryal S; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Shlobin OA; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia., Flaherty K; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan; and., Lasky J; Department of Pulmonary and Critical Care Medicine, Tulane School of Medicine, New Orleans, Louisiana., Nathan SD; Advanced Lung Disease and Transplant Program, Inova Fairfax Medical Center, Falls Church, Virginia. |
| Abstrakt: |
Rationale: Little is known about hospitalization in other types of interstitial lung disease (ILD) besides idiopathic pulmonary fibrosis (IPF). Objectives: To determine the frequency of hospitalizations in various types of ILD and elucidate the association of hospitalization with outcomes. Methods: An analysis of the Pulmonary Fibrosis Foundation Patient Registry data was performed. Inpatient hospitalization rates and survival posthospitalization were compared for various types of ILD. Measurements and Main Results: Hospitalization rates were similar across ILD types: 40.6% of participants with IPF, 42.8% of participants with connective tissue disease-related ILD (CTD-ILD), 44.9% of participants with non-IPF idiopathic interstitial pneumonia (IIP), 46.5% of participants with chronic hypersensitivity pneumonitis (CHP), and 53.3% of participants with "other" ILD. All-cause hospitalization was not associated with decreased transplant-free survival (adjusted hazard ratio [AHR], 1.20; 95% confidence interval [CI] = 0.98, 1.46; P = 0.0759) after adjusting for comorbidities and severity of illness; however, respiratory-related hospitalization was (AHR, 1.53; 95% CI = 1.23, 1.90; P = 0.0001). Participants with CTD-ILD (HR, 0.43; 95% CI = 0.25, 0.75; P = 0.0031) and non-IPF IIP (HR, 0.3; 95% CI = 0.15, 0.58; P = 0.005) had a lower risk of death posthospitalization compared with those with IPF, whereas those with chronic hypersensitivity pneumonitis (HR, 0.67; 95% CI = 0.37, 1.20; P = 0.1747) or other ILD (HR, 0.54; 95% CI = 0.19, 1.54; P = 0.25) had a risk comparable with that for IPF. Conclusions: Rates of hospitalization are similar across ILD subtypes. The risk of death or transplant after posthospitalization is lower in patients with CTD-ILD and non-IPF IIP, compared with patients with IPF. In a mixed population of participants with ILD, all-cause hospitalizations were not associated with decreased transplant-free survival; however respiratory-related hospitalizations were. |
